MARKET

APGE

APGE

Apogee Therapeutics Inc
NASDAQ
37.29
-0.52
-1.38%
After Hours: 36.97 -0.32 -0.86% 18:41 05/09 EDT
OPEN
38.14
PREV CLOSE
37.81
HIGH
39.45
LOW
36.91
VOLUME
848.27K
TURNOVER
--
52 WEEK HIGH
63.50
52 WEEK LOW
26.20
MARKET CAP
2.18B
P/E (TTM)
-11.2997
1D
5D
1M
3M
1Y
5Y
1D
APGE August 15th Options Begin Trading
NASDAQ · 1d ago
We Did The Math SMLF Can Go To $77
NASDAQ · 3d ago
Weekly Report: what happened at APGE last week (0428-0502)?
Weekly Report · 4d ago
Weekly Report: what happened at APGE last week (0421-0425)?
Weekly Report · 04/28 10:59
Weekly Report: what happened at APGE last week (0414-0418)?
Weekly Report · 04/21 10:59
Apogee Therapeutics: Engineering Biologic Dominance
Seeking Alpha · 04/14 12:04
Weekly Report: what happened at APGE last week (0407-0411)?
Weekly Report · 04/14 10:50
Apogee Therapeutics price target lowered to $78 from $80 at BofA
TipRanks · 04/08 12:35
More
About APGE
More
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
Recently
Symbol
Price
%Change

Webull offers Apogee Therapeutics Inc stock information, including NASDAQ: APGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APGE stock methods without spending real money on the virtual paper trading platform.